📊 AQST Key Takeaways
Is Aquestive Therapeutics, Inc. (AQST) a Good Investment?
Aquestive Therapeutics exhibits critical financial distress with negative stockholders equity of -$34.1M, declining revenue (-22.6% YoY), and significant operating losses exceeding -$4M quarterly. The company is burning approximately $14.8M in operating cash flow per quarter, leaving only 7-8 quarters of runway despite a strong nominal cash position. Deteriorating fundamentals and inability to achieve profitability make this a high-risk investment.
Aquestive Therapeutics shows weak underlying fundamentals, with revenue down 22.6% year over year and losses that remain far larger than the company’s revenue base. Liquidity is currently solid because of the cash balance and strong current ratio, but persistent operating cash burn, deeply negative margins, and negative equity indicate the business is still financially fragile. Until revenue stabilizes and cash burn improves materially, the fundamental profile remains unfavorable.
Aquestive Therapeutics, Inc. Key Strengths (AQST)
- Substantial cash balance of $110.7M provides near-term liquidity buffer
- Strong current ratio of 4.10x and quick ratio of 3.85x indicate adequate short-term solvency
- 21 Form 4 insider filings in last 90 days suggest ongoing management engagement
- Strong near-term liquidity with $121.17M in cash and a 3.14x current ratio
- Low capital expenditure needs, which limits additional cash strain from fixed investment
- Asset-light balance of operations may provide flexibility if revenue growth resumes
AQST Stock Risks: Aquestive Therapeutics, Inc. Investment Risks
- Negative stockholders equity of -$34.1M represents balance sheet insolvency with accumulated losses exceeding total assets
- Operating cash flow is deeply negative at -$14.8M quarterly, unsustainable without business transformation
- Revenue declining 22.6% YoY with net margin of -55.8% indicates contracting business unable to achieve scale economics
- Negative interest coverage of -0.8x means company cannot service debt obligations from operations
- Revenue contraction of 22.6% year over year suggests weak growth quality and limited operating leverage
- Severe profitability pressure with -159.5% operating margin and -188.1% net margin
- Negative free cash flow, negative interest coverage, and negative stockholders equity raise financing and balance-sheet risk
Key Metrics to Watch
- Quarterly revenue trend and inflection to positive growth
- Operating cash flow trajectory and timeline to breakeven or profitability
- Cash burn rate relative to remaining runway and any capital raises
- Revenue growth trend and commercial mix by product
- Operating cash burn and quarterly free cash flow
Aquestive Therapeutics, Inc. (AQST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.10x current ratio provides a solid financial cushion.
AQST Profit Margin, ROE & Profitability Analysis
AQST vs Healthcare Sector: How Aquestive Therapeutics, Inc. Compares
How Aquestive Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aquestive Therapeutics, Inc. Stock Overvalued? AQST Valuation Analysis 2026
Based on fundamental analysis, Aquestive Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aquestive Therapeutics, Inc. Balance Sheet: AQST Debt, Cash & Liquidity
AQST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aquestive Therapeutics, Inc.'s revenue has grown significantly by 13% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
AQST Revenue Growth, EPS Growth & YoY Performance
AQST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.7M | -$8.1M | $-0.07 |
| Q3 2025 | $12.8M | -$2.7M | $-0.13 |
| Q2 2025 | $10.0M | -$2.7M | $-0.03 |
| Q1 2025 | $8.7M | -$12.8M | $-0.17 |
| Q3 2024 | $13.0M | $241.0K | $0.00 |
| Q2 2024 | $13.2M | $2.3M | $-0.03 |
| Q1 2024 | $11.1M | $8.1M | $0.11 |
| Q3 2023 | $11.5M | $241.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aquestive Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
AQST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aquestive Therapeutics, Inc. (CIK: 0001398733)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AQST
What is the AI rating for AQST?
Aquestive Therapeutics, Inc. (AQST) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AQST's key strengths?
Claude: Substantial cash balance of $110.7M provides near-term liquidity buffer. Strong current ratio of 4.10x and quick ratio of 3.85x indicate adequate short-term solvency. ChatGPT: Strong near-term liquidity with $121.17M in cash and a 3.14x current ratio. Low capital expenditure needs, which limits additional cash strain from fixed investment.
What are the risks of investing in AQST?
Claude: Negative stockholders equity of -$34.1M represents balance sheet insolvency with accumulated losses exceeding total assets. Operating cash flow is deeply negative at -$14.8M quarterly, unsustainable without business transformation. ChatGPT: Revenue contraction of 22.6% year over year suggests weak growth quality and limited operating leverage. Severe profitability pressure with -159.5% operating margin and -188.1% net margin.
What is AQST's revenue and growth?
Aquestive Therapeutics, Inc. reported revenue of $14.4M.
Does AQST pay dividends?
Aquestive Therapeutics, Inc. does not currently pay dividends.
Where can I find AQST SEC filings?
Official SEC filings for Aquestive Therapeutics, Inc. (CIK: 0001398733) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AQST's EPS?
Aquestive Therapeutics, Inc. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AQST's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aquestive Therapeutics, Inc. has a C grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AQST stock overvalued or undervalued?
Valuation metrics for AQST: ROE of N/A (sector avg: 15%), net margin of -55.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AQST's AI grade for 2026?
Our dual AI analysis gives Aquestive Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AQST's free cash flow?
Aquestive Therapeutics, Inc.'s operating cash flow is $-14.8M, with capital expenditures of $52.0K. FCF margin is -102.9%.
How does AQST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -55.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.10 (avg: 2).